rsz_1rsz_1david_hung_mdSold Out! Pharma CEO Series:  An Evening with Dr. David Hung, CEO of Medivation

Join us for a rare and special opportunity to listen to Dr. David Hung — one of the most successful biotech entrepreneurs in the world — in a fireside chat moderated by CapellaBio CEO Dr. Pek Lum.

David Hung, M.D., founded Medivation in October 2003, taking the company public through a reverse merger in December 2004 and subsequently raising a total of $440MM in public offerings over the life of the company. He established partnerships with world-class pharmaceutical companies (Pfizer and Astellas) worth ~$1.5B in upfront payments and milestones, excluding profit splits and royalties, with both partners paying the majority of development costs. In October 2016, Medivation was sold to Pfizer for $14.3B all-cash deal, the largest sale of a biopharma company by an actively-seated founding CEO.


Prior to Medivation, David was President & Chief Executive Officer of Pro•Duct Health, Inc., a venture-backed startup medical device company founded in 1998 which developed, manufactured, and commercialized a breast microcatheter — which he himself invented — for a minimally invasive procedure called ductal lavage for breast cancer risk assessment. After raising a total of $22MM in venture capital, Pro•Duct Health was acquired in 2001 for $168MM by Cytyc Corporation. 


David previously spent several years in pre-clinical research and development roles of increasing responsibility at Chiron Corporation. Earlier in his career, David was a practicing physician at the hospitals and clinics of the University of California, San Francisco, holding positions such as: Division Chief, Transfusion Medicine Division; Attending Physician, Hematology-Oncology/Transfusion Medicine; and, Assistant Professor in Residence, Department of Laboratory Medicine. There, he also completed basic science research fellowships at the Brain Tumor Research Institute and the Cardiovascular Research Institute (CVRI), as well as fellowships in Hematology, Oncology and Transfusion Medicine.

He received his A.B., summa cum laude, in Biology and Organic Chemistry from Harvard College, and his M.D., Alpha Omega Alpha, from the University of California, San Francisco School of Medicine.


David is an avid violinist (formerly the Concert Master of the Waltham Symphony Orchestra) and pianist, tennis player, former 7-handicap golfer, and former head chef at Marco Polo, a pop-up Italian-Asian fusion restaurant he started as a summer vacation project.


Pek Lum, our moderator, is the founder and CEO of CapellaBio. CapellaBio ( is a VC funded computational pharmaceutical company based in Palo Alto, CA. Pek is a biologist who has been in data, software and pharmaceuticals for the past 17 years. Pek’s initial start in genomics was with Rosetta Inpharmatics, a genomics and microarray company that went public and was subsequently bought by Merck & Co. Pek spent another 8 years at Merck applying data, algorithms and biology to Merck’s drug discovery pipeline. Most recently, she was the VP of Product and Chief Data Scientist for Ayasdi, an enterprise software company. Pek received her B.S. and M.S. from Hokkaido University, Japan and her Ph.D. from the University of Washington, Seattle.




Thursday, November 3, 2016
6:30 PM — 8:30 PM
Gibson Dunn
555 Mission St., San Francisco
Doorman will open door and escort to offices
$25 per person
Registration required by Nov. 2, 2016
No refunds after Nov. 2, 2016

Organizers: Anupan Agarwal, MPH ’05 & Eli Salomon, HLS ‘06
Question? Please contact